EmCyte Announces FDA 510(k) Clearance for its PurePRP(R) Supraphysiologic Concentrating System
FORT MYERS, Fla., Feb. 25, 2020 -- (Healthcare Sales &Marketing Network) -- EmCyte, the world leader in platelet rich plasma and progenitor stem cell biologics, announces its FDA 510(k) clearance for its PurePRP® Supraphysiologic Concentrating System... Devices, FDA EmCyte, PurePRP, Supraphysiologic Concentrating System
Authors: Li L, Zheng Y, Zheng Q, Jiang J Abstract The present study aimed to investigate the antiproliferative effect of embryonic stem cell-conditioned medium (ESC-CM) on the mouse liver cancer Hepa1-6 cells in vitro. Furthermore, in order to elucidate the underlying molecular mechanism, the microRNAs (miRNAs) in ESC-CM associated with the inhibition of Hepa1-6 proliferation were identified. Following the co-culture of ESC-CM and Hepa1-6 in Transwell chambers, the proliferation, cell cycle, apoptosis and associated protein expression were determined in Hepal-6 cells. Moreover, miRNA array analysis was employed to ...
Conclusions: LSCD associated with glaucoma surgery has clinical features distinct from LSCD resulting from other etiologies. Further study is required to delineate the full impact of glaucoma surgery on limbal stem cell function and survival.
Conclusions: The intimate relationship between epithelium and sensory nerves of the cornea has been well documented; however, changes in the corneal epithelial stem cell niche in conjunction with development of innervation have not previously been reported. Considering the architecture of the corneal nerves in conjunction with the architecture of the POV may assist in developing treatments that can support the regeneration and maintenance of epithelium during nerve regeneration.
Publication date: 31 March 2020Source: Cell Reports, Volume 30, Issue 13Author(s): Yue Zhang, Guoping Liu, Teng Guo, Xiaoyi G. Liang, Heng Du, Lin Yang, Aparna Bhaduri, Xiaosu Li, Zhejun Xu, Zhuangzhi Zhang, Zhenmeiyu Li, Miao He, Jeremiah Tsyporin, Arnold R. Kriegstein, John L. Rubenstein, Zhengang Yang, Bin Chen
SAN DIEGO, April 1, 2020 -- (Healthcare Sales &Marketing Network) -- Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the close of its Series A fund... Regenerative Medicine, Neurology, Venture Capital Aspen Neuroscience, Parkinson, stem cell
CONCLUSION: Our results indicated that MSC-secretome had DPP-IV/CD26 and APN/CD13 activity. The DPP-IV/CD26 activity was decreased following stimulation of MSCs by toll-like receptor 4 agonist. Further studies are needed to reveal the possible contribution of DPP-IV/CD26 and APN/CD13 in the anti-inflammatory functions of MSC-CM. PMID: 32224540 [PubMed - in process]
While a group of stem cells within the intestine has been the main culprit for the growth of cancer, nearby fibroplats may harbor the real molecular villains.
Researchers here consider a very conservative set of interventions known to modestly slow the progression of aging in laboratory species, largely by altering metabolism to upregulate beneficial cellular stress responses. The researchers look through the lens of lung aging, specifically, reviewing the evidence for these therapies to slow the deterioration in lung function and onset of lung disease in older individuals, or to be the basis for treating established lung disease. To date, the most reliable, best-researched way to extend life span is through the practice of calorie restriction (CR), which involves reduc...
Publication date: April 2020Source: Stem Cell Research, Volume 44Author(s): Yalan Zhou, Chengcheng Ding, Shutao Xia, Yutong Jing, Shengru Mao, Jian Liu, Juan Chen, Hon fai Chan, Shibo Tang, Jiansu Chen
We report the Single Cell analysis of Tcf4 Lin- cells isolated from the mouse colon.